GlassScriptPhysician profile
Gary Ciambotti
NPI 1356327183
$22,832.75
in general payments reported to CMS, 2019-2025
44 companies · $4,044 in 2025
The $4,044 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,220 · 2020: $1,420 · 2021: $1,333 · 2022: $7,085 · 2023: $2,073 · 2024: $3,657 · 2025: $4,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,640 · Education: $91.95 · Long Term Medical Supply Or Device Loan: $42.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,640.03 |
| Education | $91.95 |
| Long Term Medical Supply Or Device Loan | $42.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $6,494.93 | 2019-2025 | Linzess |
| Abbvie INC. | $3,230.59 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $2,221.27 | 2019-2025 | Tremfya, Stelara |
| Allergan, INC. | $1,758.87 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,313.30 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,202.01 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Lilly USA, LLC | $636.07 | 2024-2025 | Omvoh, Zepbound |
| Janssen Scientific Affairs, LLC | $592.43 | 2024-2025 | Tremfya, Stelara |
| Genzyme Corporation | $577.41 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $498.79 | 2024-2025 | Voquezna |
| Pfizer INC. | $481.31 | 2019-2025 | |
| Qol Medical, LLC | $357.83 | 2019-2024 | Sucraid, Sucraid |
| Celltrion USA INC. | $349.03 | 2024-2025 | Vegzelma, Zymfentra |
| Intercept Pharmaceuticals, INC. | $344.30 | 2019-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $330.81 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $323.24 | 2022-2025 | Ibsrela |
| Celgene Corporation | $249.37 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $235.40 | 2019-2023 | Dificid, Zinplava |
| Amgen INC. | $228.55 | 2019-2025 | Uplizna |
| Ipsen Biopharmaceuticals, INC | $206.41 | 2024-2025 | Iqirvo, Bylvay |
| Daiichi Sankyo INC. | $162.00 | 2019-2024 | Injectafer |
| Gilead Sciences, INC. | $156.10 | 2019-2025 | |
| Novo Nordisk INC | $134.54 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $99.61 | 2023-2024 | Rebyota, Cimzia |
| Regeneron Healthcare Solutions, INC. | $63.86 | 2022-2024 | Dupixent |
| Organon LLC | $60.78 | 2021-2023 | Renflexis, Hadlima |
| Redhill Biopharma INC. | $56.53 | 2020-2022 | |
| Ethicon US, LLC | $45.13 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $44.93 | 2023-2025 | Zenpep |
| Alfasigma USA, INC. | $42.65 | 2020 | |
| Pentax of America, INC. | $42.38 | 2024 | Endo Stratus Co2 Insufflator |
| Ucb, INC. | $36.24 | 2019 | |
| Braintree Laboratories, INC. | $33.56 | 2019-2023 | Sutab |
| Nestle Healthcare Nutrition INC. | $30.17 | 2020-2021 | |
| Medtronic, INC. | $28.05 | 2022 | |
| Intra-Sana Laboratories | $26.10 | 2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Boston Scientific Corporation | $23.97 | 2025 | Resolution 360 Clip |
| Sanofi Pasteur INC. | $19.62 | 2024 | |
| Sanofi US Services INC. | $19.27 | 2025 | |
| Fresenius Kabi USA, LLC | $17.90 | 2023 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.14 | 2023 | Cyltezo |
| Orphalan INC | $14.22 | 2024 | Cuvrior |
| Shire North American Group INC | $13.89 | 2019 | |
| Endo Pharmaceuticals INC. | $12.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Ciambotti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.